The extreme COOH terminus of the retinoblastoma tumor suppressor protein pRb is required for phosphorylation on Thr-373 and activation of E2F

American Journal of Physiology - Cell Physiology

Volumn 295, Issue 5, 2008, Pages

  Gorges, Laura L ^a   Lents, Nathan H ^b   Baldassare, Joseph J ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

^b JOHN JAY COLLEGE OF CRIMINAL JUSTICE   (United States)

Author keywords

Cell cycle; Cyclin

Indexed keywords

CARBOXYLIC ACID; CYCLIN E; RETINOBLASTOMA PROTEIN; THREONINE; TRANSCRIPTION FACTOR E2F;

ARTICLE; CELL CYCLE S PHASE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RETINOBLASTOMA;

BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; GENES, REPORTER; HUMANS; MUTATION; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RETINOBLASTOMA PROTEIN; S PHASE; THREONINE; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 57349172673     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00300.2008     Document Type: Article

References (79)

1. Bagchi S, Raychaudhuri P, Nevins JR. Adenovirus E1A proteins can dissociate heteromeric complexes involving the E2F transcription factor: a novel mechanism for E1A trans-activation. Cell 62: 659-669, 1990.
2. Bagchi S, Weinmann R, Raychaudhuri P. The retinoblastoma protein copurifies with E2F-I, an E1A-regulated inhibitor of the transcription factor E2F. Cell 65: 1063-1072, 1991.
3. Bandara LR, La Thangue NB. Adenovirus E1a prevents the retinoblastoma gene product from complexing with a cellular transcription factor. Nature 351: 494-497, 1991.
4. Bookstein R, Shew JY, Chen PL, Scully P, Lee WH. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247: 712-715, 1990.
5. Bortner DM, Rosenberg MP. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 17: 453-459, 1997.
6. Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391: 597-601, 1998.
7. Buchkovich K, Duffy LA, Harlow E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58: 1097-1105, 1989.
8. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the RB protein. Cell 65: 1053-1061, 1991.
9. Chen PL, Scully P, Shew JY, Wang JY, Lee WH. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 58: 1193-1198, 1989.
10. Chittenden T, Livingston DM, Kaelin WG Jr. The T/E1A-binding domain of the retinoblastoma product can interact selectively with a sequence-specific DNA-binding protein. Cell 65: 1073-1082, 1991.
11. Connell-Crowley L, Harper JW, Goodrich DW. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell 8: 287-301, 1997.
12. 1/S-regulatory genes. Mol Cell Biol 15: 4215-4224, 1995.
13. Dou QP, Pardee AB, Keyomarsi K. Cyclin E - a better prognostic marker for breast cancer than cyclin D? Nat Med 2: 254, 1996.
14. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73: 499-511, 1993.
15. Dynlacht BD, Flores O, Lees JA, Harlow E. Differential regulation of E2F transactivation by cyclin/cdk2 complexes. Genes Dev 8: 1772-1786, 1994.
16. Dynlacht BD, Moberg K, Lees JA, Harlow E, Zhu L. Specific regulation of E2F family members by cyclin-dependent kinases. Mol Cell Biol 17: 3867-3875, 1997.
17. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 12: 2245-2262, 1998.
18. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243: 934-937, 1989.
19. 1 cyclin-dependent kinase complexes in vivo. Mol Cell Biol 21: 4773-4784, 2001.
20. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323: 643-646, 1986.
21. qα in α-thrombin-mediated mitogenic signalling pathways. Cell Signal 14: 499-507, 2002.
22. Geisen C, Moroy T. The oncogenic activity of cyclin E is not confined to Cdk2 activation alone but relies on several other, distinct functions of the protein. J Biol Chem 277: 39909-39918, 2002.
23. Geng Y, Eaton EN, Picón M, Roberts JM, Lundberg AS, Gifford A, Sardet C, Weinberg RA. Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene 12: 1173-1180, 1996.
24. 1 phase of the cell cycle. Cell 67: 293-302, 1991.
25. Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, DeCaprio JA, Keyomarsi K. Cyclin E, a redundant cyclin in breast cancer. Proc Natl Acad Sci USA 93: 15215-15220, 1996.
26. Harbour JW, Dean DC. Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol 2: E65-E67, 2000.
27. Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241: 353-357, 1988.
28. 1. Cell 98: 859-869, 1999.
29. Harwell RM, Porter DC, Danes C, Keyomarsi K. Processing of cyclin E differs between normal and tumor breast cells. Cancer Res 60: 481-489, 2000.
30. Hassler M, Singh S, Yue WW, Luczynski M, Lakbir R, Sanchez-Sanchez F, Bader T, Pearl LH, Mittnacht S. Crystal structure of the retinoblastoma protein N domain provides insight into tumor suppression, ligand interaction, and holoprotein architecture. Mol Cell 28: 371-385, 2007.
31. 1 cyclins in the functional inactivation of the retinoblastoma protein. Genes Dev 8: 1759-1771, 1994.
32. Helin K, Harlow E, Fattaey A. Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Mol Cell Biol 13: 6501-6508, 1993.
33. Hiebert SW, Chellappan SP, Horowitz JM, Nevins JR. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev 6: 177-185, 1992.
34. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70: 993-1006, 1992.
35. Hogg A, Bia B, Onadim Z, Cowell JK. Molecular mechanisms of oncogenic mutations in tumors from patients with bilateral and unilateral retinoblastoma. Proc Natl Acad Sci USA 90: 7351-7355, 1993.
36. Horowitz JM, Yandell DW, Park SH, Canning S, Whyte P, Buchkovich K, Harlow E, Weinberg RA, Dryja TP. Point mutational inactivation of the retinoblastoma antioncogene. Science 243: 937-940, 1989.
37. Hu QJ, Dyson N, Harlow E. The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations. EMBO J 9: 1147-1155, 1990.
38. Huang HJ, Yee JK, Shew JY, Chen PL, Bookstein R, Friedmann T, Lee EY, Lee WH. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242: 1563-1566, 1988.
39. Huang S, Wang NP, Tseng BY, Lee WH, Lee EH. Two distinct and frequently mutated regions of retinoblastoma protein are required for binding to SV40 T antigen. EMBO J 9: 1815-1822, 1990.
40. Kaelin WG Jr. Functions of the retinoblastoma protein. Bioessays 21: 950-958, 1999.
41. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7: 331-342, 1993.
42. 1-S phase progression. J Biol Chem 279: 5387-5396, 2004.
43. Keyomarsi K, Conte D Jr, Toyofuku W, Fox MP. Deregulation of cyclin E in breast cancer. Oncogene 11: 941-950, 1995.
44. Keyomarsi K, Herliczek TW. The role of cyclin E in cell proliferation, development and cancer. Prog Cell Cycle Res 3: 171-191, 1997.
45. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 54: 380-385, 1994.
46. Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci USA 90: 1112-1116, 1993.
47. Keyomarsi K, Tucker SL, Bedrosian I. Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. Nat Med 9: 152, 2003.
48. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS. Cyclin E and survival in patients with breast cancer. N Engl J Med 347: 1566-1575, 2002.
49. Kitahara K, Yasui W, Kuniyasu H, Yokozaki H, Akama Y, Yunotani S, Hisatsugu T, Tahara E. Concurrent amplification of cyclin E and CDK2 genes in colorectal carcinomas. Int J Cancer 62: 25-28, 1995.
50. Knudsen KE, Fribourg AF, Strobeck MW, Blanchard JM, Knudsen ES. Cyclin A is a functional target of retinoblastoma tumor suppressor protein-mediated cell cycle arrest. J Biol Chem 274: 27632-27641, 1999.
51. Kuhling H, Alm P, Olsson H, Ferno M, Baldetorp B, Parwaresch R, Rudolph P. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J Pathol 199: 424-431, 2003.
52. Lee EY, To H, Shew JY, Bookstein R, Scully P, Lee WH. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 241: 218-221, 1988.
53. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235: 1394-1399, 1987.
54. Lees JA, Buchkovich KJ, Marshak DR, Anderson CW, Harlow E. The retinoblastoma protein is phosphorylated on multiple sites by human cdc2. EMBO J 10: 4279-4290, 1991.
55. 1 cyclin-dependent kinases in the absence of retinoblastoma protein phosphorylation. Curr Biol 7: 709-712, 1997.
56. Lents NH, Baldassare JJ. CDK2 and cyclin E knockout mice: lessons from breast cancer. Trends Endocrinol Metab 15: 1-3, 2004.
57. Lents NH, Gorges LL, Baldassare JJ. Reverse mutational analysis reveals threonine-373 as a potentially sufficient phosphorylation site for inactivation of the retinoblastoma tumor suppressor protein (pRB). Cell Cycle 5: 1699-1707, 2006.
58. Lukas J, Herzinger T, Hansen K, Moroni MC, Resnitzky D, Helin K, Reed SI, Bartek J. Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes Dev 11: 1479-1492, 1997.
59. Luo RX, Postigo AA, Dean DC. Rb interacts with histone deacetylase to repress transcription. Cell 92: 463-473, 1998.
60. Mihara K, Cao XR, Yen A, Chandler S, Driscoll B, Murphree AL, T'Ang A, Fung YK. Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product. Science 246: 1300-1303, 1989.
61. Mittnacht S, Lees JA, Desai D, Harlow E, Morgan DO, Weinberg RA. Distinct sub-populations of the retinoblastoma protein show a distinct pattern of phosphorylation. EMBO J 13: 118-127, 1994.
62. 1/S phosphorylation of the retinoblastoma protein is associated with an altered affinity for the nuclear compartment. Cell 65: 381-393, 1991.
63. Nielsen SJ, Schneider R, Bauer UM, Bannister AJ, Morrison A, O'Carroll D, Firestein R, Cleary M, Jenuwein T, Herrera RE, Kouzarides T. Rb targets histone H3 methylation and HP1 to promoters. Nature 412: 561-565, 2001.
64. Ohtani K, DeGregori J, Nevins JR. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci USA 92: 12146-12150, 1995.
65. Qian Y, Luckey C, Horton L, Esser M, Templeton DJ. Biological function of the retinoblastoma protein requires distinct domains for hyperphosphorylation and transcription factor binding. Mol Cell Biol 12: 5363-5372, 1992.
66. Qin XQ, Chittenden T, Livingston DM, Kaelin WG. Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev 6: 953-964, 1992.
67. Rubin SM, Gall AL, Zheng N, Pavletich NP. Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release. Cell 123: 1093-1106, 2005.
68. Rudolph P, Kuhling H, Alm P, Ferno M, Baldetorp B, Olsson H, Parwaresch R. Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Int J Cancer 105: 674-680, 2003.
69. Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilber K, Seelig S, Kononen J, Mihatsch MJ, Dirnhofer S, Sauter G. Cyclin E overexpression and amplification in human tumours. J Pathol 200: 375-382, 2003.
70. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2: 103-112, 2002.
71. Span PN, Tjan-Heijnen VC, Manders P, Beex LV, Sweep CG. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 22: 4898-4904, 2003.
72. Strobeck MW, Fribourg AF, Puga A, Knudsen ES. Restoration of retinoblastoma mediated signaling to Cdk2 results in cell cycle arrest. Oncogene 19: 1857-1867, 2000.
73. Strobeck MW, Knudsen KE, Fribourg AF, DeCristofaro MF, Weissman BE, Imbalzano AN, Knudsen ES. BRG-1 is required for RB-mediated cell cycle arrest. Proc Natl Acad Sci USA 97: 7748-7753, 2000.
74. Vandel L, Nicolas E, Vaute O, Ferreira R, Ait-Si-Ali S, Trouche D. Transcriptional repression by the retinoblastoma protein through the recruitment of a histone methyltransferase. Mol Cell Biol 21: 6484-6494, 2001.
75. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.
76. Yandell DW, Campbell TA, Dayton SH, Petersen R, Walton D, Little JB, McConkie-Rosell A, Buckley EG, Dryja TP. Oncogenic point mutations in the human retinoblastoma gene: their application to genetic counseling. N Engl J Med 321: 1689-1695, 1989.
77. 1/S cyclin-dependent kinases. J Biol Chem 272: 12738-12746, 1997.
78. 1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/ SNF. Cell 101: 79-89, 2000.
79. Zhou Y, Li J, Xu K, Hu S, Benedict WF. Further characterization of retinoblastoma gene-mediated cell growth and tumor suppression in human cancer cells. Proc Natl Acad Sci USA 91: 4165-4169, 1994.